MCID: CLD010
MIFTS: 46

Cold-Induced Sweating Syndrome 1 malady

Categories: Genetic diseases, Rare diseases, Neuronal diseases

Aliases & Classifications for Cold-Induced Sweating Syndrome 1

About this section
Sources:
11Disease Ontology, 12diseasecard, 13DISEASES, 25Genetics Home Reference, 27GTR, 30ICD10, 31ICD10 via Orphanet, 37MedGen, 39MeSH, 40MESH via Orphanet, 48NIH Rare Diseases, 50Novoseek, 52OMIM, 54Orphanet, 62SNOMED-CT, 64The Human Phenotype Ontology, 68UMLS, 69UMLS via Orphanet, 70UniProtKB/Swiss-Prot
See all MalaCards sources

Aliases & Descriptions for Cold-Induced Sweating Syndrome 1:

Name: Cold-Induced Sweating Syndrome 1 52 70 27 12 68
Crisponi Syndrome 11 48 25 54 70 50 39 68
Cold-Induced Sweating Syndrome 11 25 54 27 12 50 13
Sohar-Crisponi Syndrome 11 25 70
Ciss 25 54
 
Muscle Contractions, Tetanoform, with Characteristic Face, Camptodactyly, Hyperthermia, and Sudden Death 48
Muscle Contractions Tetanoform with Characteristic Face Camptodactyly Hyperthermia and Sudden Death 70
Cntf Receptor-Related Disorders 25
Hyperhidrosis 39
Ciss1 70

Characteristics:

Orphanet epidemiological data:

54
cold-induced sweating syndrome:
Inheritance: Autosomal recessive; Prevalence: <1/1000000 (Worldwide); Age of onset: Adult,Childhood; Age of death: normal life expectancy
crisponi syndrome:
Inheritance: Autosomal recessive; Prevalence: <1/1000000 (Worldwide); Age of onset: Neonatal

HPO:

64
cold-induced sweating syndrome 1:
Inheritance: autosomal recessive inheritance

Classifications:



External Ids:

OMIM52 272430
Disease Ontology11 DOID:0060294
ICD10 via Orphanet31 G90.8
SNOMED-CT62 702363009
MESH via Orphanet40 C536214
UMLS via Orphanet69 C1832409
ICD1030 R61, R61.9

Summaries for Cold-Induced Sweating Syndrome 1

About this section
OMIM:52 Cold-induced sweating syndrome is an autosomal recessive disorder characterized in the neonatal period by orofacial... (272430) more...

MalaCards based summary: Cold-Induced Sweating Syndrome 1, also known as crisponi syndrome, is related to cold-induced sweating syndrome 2 and cold-induced sweating syndrome 3, and has symptoms including full cheeks, long philtrum and anteverted nares. An important gene associated with Cold-Induced Sweating Syndrome 1 is CRLF1 (Cytokine Receptor Like Factor 1), and among its related pathways are CNTF Signaling and Translation Insulin regulation of translation. Affiliated tissues include skin, and related mouse phenotypes are behavior/neurological and nervous system.

Disease Ontology:11 An autosomal dominant disease characterized by problems with regulating body temperature and other abnormalities affecting many parts of the body. It has material basis in mutations in the CRLF1 gene.

Genetics Home Reference:25 Cold-induced sweating syndrome is characterized by problems with regulating body temperature and other abnormalities affecting many parts of the body. In infancy, the features of this condition are often known as Crisponi syndrome. Researchers originally thought that cold-induced sweating syndrome and Crisponi syndrome were separate disorders, but it is now widely believed that they represent the same condition at different times during life.

UniProtKB/Swiss-Prot:70 Cold-induced sweating syndrome 1: An autosomal recessive disorder characterized by profuse sweating induced by cool surroundings (temperatures of 7 to 18 degrees Celsius). Patients manifest, in the neonatal period, orofacial weakness with impaired sucking and swallowing, resulting in poor feeding. Affected infants show a tendency to startle, with contractions of the facial muscles in response to tactile stimuli or during crying, trismus, abundant salivation, and opisthotonus. These features are referred to as Crisponi syndrome and can result in early death in infancy. Patients who survive into childhood have hyperhidrosis, mainly of the upper body, in response to cold temperatures, and sweat very little with heat. Additional abnormalities include a high-arched palate, nasal voice, depressed nasal bridge, inability to fully extend the elbows and kyphoscoliosis.

Related Diseases for Cold-Induced Sweating Syndrome 1

About this section

Graphical network of the top 20 diseases related to Cold-Induced Sweating Syndrome 1:



Diseases related to cold-induced sweating syndrome 1

Symptoms & Phenotypes for Cold-Induced Sweating Syndrome 1

About this section

Symptoms by clinical synopsis from OMIM:

272430

Clinical features from OMIM:

272430

Human phenotypes related to Cold-Induced Sweating Syndrome 1:

 64 54 (show all 46)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 full cheeks64 54 hallmark (90%) Very frequent (99-80%) HP:0000293
2 long philtrum64 54 hallmark (90%) Very frequent (99-80%) HP:0000343
3 anteverted nares64 54 hallmark (90%) Very frequent (99-80%) HP:0000463
4 hypohidrosis64 54 hallmark (90%) Very frequent (99-80%) HP:0000966
5 hyperhidrosis64 54 hallmark (90%) Very frequent (99-80%) HP:0000975
6 hypertonia64 54 hallmark (90%) Very frequent (99-80%) HP:0001276
7 sudden cardiac death64 54 hallmark (90%) Very frequent (99-80%) HP:0001645
8 malignant hyperthermia64 54 hallmark (90%) Very frequent (99-80%) HP:0002047
9 respiratory insufficiency64 54 hallmark (90%) Very frequent (99-80%) HP:0002093
10 scoliosis64 54 hallmark (90%) Very frequent (99-80%) HP:0002650
11 kyphosis64 54 hallmark (90%) Very frequent (99-80%) HP:0002808
12 camptodactyly of finger64 54 hallmark (90%) Very frequent (99-80%) HP:0100490
13 large face64 54 hallmark (90%) Very frequent (99-80%) HP:0100729
14 abnormality of the palate64 typical (50%) HP:0000174
15 limitation of joint mobility64 54 typical (50%) Frequent (79-30%) HP:0001376
16 cognitive impairment64 54 typical (50%) Frequent (79-30%) HP:0100543
17 narrow mouth64 54 occasional (7.5%) Occasional (29-5%) HP:0000160
18 micrognathia64 54 occasional (7.5%) Occasional (29-5%) HP:0000347
19 seizures64 54 occasional (7.5%) Occasional (29-5%) HP:0001250
20 intellectual disability64 rare (5%) HP:0001249
21 high palate64 54 Frequent (79-30%) HP:0000218
22 retrognathia64 HP:0000278
23 low-set ears64 HP:0000369
24 wide nose64 54 Very frequent (99-80%) HP:0000445
25 short neck64 HP:0000470
26 carious teeth64 HP:0000670
27 adducted thumb64 HP:0001181
28 tapered finger64 HP:0001182
29 limited elbow extension64 HP:0001377
30 nasal speech64 HP:0001611
31 talipes equinovarus64 HP:0001762
32 pes planus64 HP:0001763
33 episodic fever64 HP:0001954
34 dyspnea64 HP:0002094
35 opisthotonus64 HP:0002179
36 kyphoscoliosis64 HP:0002751
37 elbow flexion contracture64 HP:0002987
38 short palm64 HP:0004279
39 depressed nasal bridge64 HP:0005280
40 feeding difficulties in infancy64 HP:0008872
41 radial deviation of finger64 HP:0009466
42 facial palsy64 HP:0010628
43 camptodactyly64 HP:0012385
44 flexion contracture54 Very frequent (99-80%)
45 death in infancy54 Very frequent (99-80%)
46 feeding difficulties54 Very frequent (99-80%)

UMLS symptoms related to Cold-Induced Sweating Syndrome 1:


dyspnea, opisthotonus, facial paresis

MGI Mouse Phenotypes related to Cold-Induced Sweating Syndrome 1 according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053868.1CLCF1, CNTF, CNTFR, CRLF1, LIFR, SORL1
2MP:00036317.3CLCF1, CNTF, CNTFR, CRLF1, LIFR, SORL1

Drugs & Therapeutics for Cold-Induced Sweating Syndrome 1

About this section

Drugs for Cold-Induced Sweating Syndrome 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 52)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
PrazosinapprovedPhase 46219216-56-94893
Synonyms:
1-(3-Amino-6,7-dimethoxy-2- quinazolinyl)-4-(2-furanyl-carbonyl)piperazine hydrochloride
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl) piperazine
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine
19216-56-9
2-(4-(2-Furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazoline
2-[4-(2-furoyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine
4-(4-Amino-6,7-dimethoxyquinazolin-2-yl)piperazinyl 2-furyl ketone
5-25-13-00365 (Beilstein Handbook Reference)
AB00053528
AC1L1J6T
AKOS000310009
BCBcMAP01_000227
BPBio1_001006
BRD-K49111258-001-02-8
BRD-K49111258-003-05-7
BRN 0768345
BSPBio_000914
BSPBio_001036
BSPBio_002221
Bio1_000365
Bio1_000854
Bio1_001343
Bio2_000358
Bio2_000838
C07368
C19H21N5O4
CAS-19237-84-4
CHEBI:8364
CHEMBL2
CID4893
CP-12299
D08411
DB00457
DivK1c_000375
EINECS 242-885-8
Furazosin
HMS1362D17
HMS1792D17
HMS1990D17
HMS2089G09
HSDB 3298
IDI1_000375
IDI1_002113
Justac
KBio1_000375
KBio2_000376
KBio2_001302
KBio2_002944
KBio2_003870
KBio2_005512
KBio2_006438
KBio3_000731
KBio3_000732
KBio3_001721
KBioGR_000376
KBioGR_000965
KBioSS_000376
KBioSS_001302
 
L000666
LS-140002
Lentopres
Minipress
Minipress (TN)
Minipress Xl
MolPort-000-891-036
NCGC00016740-01
NCGC00016740-02
NCGC00016740-03
NCGC00016740-14
NCGC00024324-02
NCGC00024324-04
NCGC00024324-05
NCGC00024324-06
NCGC00024324-07
NCGC00024324-08
NCGC00024324-09
NCI60_002417
NINDS_000375
Oprea1_314778
Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)- (9CI)
Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)- (8CI)
Prazocin
Prazosin (INN)
Prazosin HCl
Prazosin Hydrochloride
Prazosin [INN:BAN]
Prazosina
Prazosina [INN-Spanish]
Prazosine
Prazosine [INN-French]
Prazosinum
Prazosinum [INN-Latin]
Prestwick0_000947
Prestwick1_000947
Prestwick2_000947
Prestwick3_000947
SMP1_000063
SPBio_001297
SPBio_003073
ST075549
STK301545
Spectrum2_001289
Spectrum3_000551
Spectrum4_000483
Spectrum5_001365
Spectrum_000822
TL8001573
TNP00312
Tocris-0623
UNII-XM03YJ541D
Vasoflex
ZINC00601304
[3H]-Prazosin
[4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-(2-furyl)methanone
[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl](furan-2-yl)methanone
[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(furan-2-yl)methanone
prazosin
2
AcetylcholineapprovedPhase 4, Phase 3, Phase 2, Phase 177651-84-3187
Synonyms:
ACh
Acetyl choline ion
Acetylcholine Chloride
Acetylcholine cation
 
Acetylcholinium: acetyl-Choline
Choline acetate
Choline acetate (ester)
O-Acetylcholine
acetylcholine chloride
3
TerazosinapprovedPhase 42163590-64-75401
Synonyms:
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)piperazine
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(tetrahydro-2-furoyl)piperazine
6,7-bis(methyloxy)-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine
6,7-dimethoxy-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine
63074-08-8 (hydrochloride)
63590-64-7
70024-40-7 (mono-hydrochloride, dihydrate)
A 45975
A-45975
AC-11120
AC1L1K9W
Abbott 45975
BPBio1_000840
BRD-A22256192-003-03-7
BSPBio_000762
Blavin
C07127
C19H25N5O4
CHEBI:9445
CHEMBL611
CID5401
CPD000058309
D08569
DB01162
Flumarc
Fosfomic
HMS2090P21
Hytracin
Hytrin
L000692
LS-110234
 
Lopac0_001138
MLS000069703
MLS001201836
MLS001305722
MolPort-001-684-489
NCGC00016026-08
NCGC00025191-03
Prestwick0_000751
Prestwick1_000751
Prestwick2_000751
Prestwick3_000751
SAM002589982
SMR000058309
SPBio_002701
STK567029
STOCK4S-28262
Terazosabb
Terazosabb (TN)
Terazosin
Terazosin (INN)
Terazosin [INN:BAN]
Terazosina
Terazosina [INN-Spanish]
Terazosine
Terazosine [INN-French]
Terazosinum
Terazosinum [INN-Latin]
Trazosin HCl
UNII-8L5014XET7
Vasomet
[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl](tetrahydrofuran-2-yl)methanone
[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone
terazosin
4
Oxybutyninapproved, investigationalPhase 4, Phase 3, Phase 2675633-20-54634
Synonyms:
1508-65-2 (hydrochloride)
4-(Diethylamino)-2-butynyl alpha-phenylcyclohexaneglycolic acid ester
4-(diethylamino)-2-butynyl-alpha-cyclohexyl-alpha-hydroxybenzeneacetate
4-(diethylamino)-2-butynyl-alpha-phenylcyclohexaneglycolate
4-(diethylamino)but-2-yn-1-yl cyclohexyl(hydroxy)phenylacetate
4-(diethylamino)but-2-ynyl 2-cyclohexyl-2-hydroxy-2-phenylacetate
4-Diethylamino-2-butinyl alpha-cyclohexylmandelat
4-Diethylamino-2-butynyl alpha-phenylcyclohexaneglycolate
5633-20-5
AC-2153
AC1L1ILV
BPBio1_000214
BRD-A65013509-003-03-8
BSPBio_000194
Benzeneacetic acid, alpha-cyclohexyl-alpha-hydroxy-, 4-(diethylamino)-2-butynyl ester
C07360
CCRIS 1923
CHEBI:7856
CHEMBL1231
CID4634
Cyclohexaneglycolic acid, .alpha.-phenyl-, 4-(diethylamino)-2-butynyl ester
Cyclohexaneglycolic acid, alpha-phenyl-, 4-(diethylamino)-2-butynyl ester
Cystrin
D00465
DB01062
Ditropan
Ditropan, Lyrinel XL, Oxytrol, Oxybutynin
FT-0082890
HSDB 3270
I06-2117
L000923
LS-28714
 
Lopac0_000923
MolPort-003-849-741
NCGC00015767-06
NCGC00089795-02
Oxibutinina
Oxibutinina [INN-Spanish]
Oxibutyninum
Oxybutinin
Oxybutynin
Oxybutynin (USAN/INN)
Oxybutynin Base
Oxybutynin Chloride
Oxybutynin Hydrochloride
Oxybutynin [USAN:INN:BAN]
Oxybutynin topical gel
Oxybutynine
Oxybutynine [INN-French]
Oxybutyninum
Oxybutyninum [INN-Latin]
Oxytrol
Oxytrol (TN)
Pollakisu
Prestwick0_000287
Prestwick1_000287
Prestwick2_000287
Prestwick3_000287
S1754_Selleck
SPBio_002413
Transdermal patch
UNII-K9P6MC7092
oxybutynin
oxybutynin topical gel
transdermal patch
5
LevodopaapprovedPhase 438859-92-76047
Synonyms:
(-)-(3,4-Dihydroxyphenyl)alanine
(-)-3-(3,4-Dihydroxyphenyl)-L-alanine
(-)-3-(3,4-dihydroxyphenyl)-L-alanine
(-)-Dopa
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid
(−)-3-(3,4-dihydroxyphenyl)-L-alanine
(−)-dopa
.Beta.-(3, 4-Dihydroxyphenyl)alanine
.Beta.-(3,4-Dihydroxyphenyl)-L-alanine
1E83F927-C221-46AA-B90A-81B33C5F3868
2-Amino-3-(3,4-dihydroxyphenyl)propanoic acid
23734-74-9
25525-15-9
3, 4-Dihydroxy-L-phenylalanine
3, 4-Dihydroxyphenylalanine
3,4-DIHYDROXYPHENYLALANINE
3,4-Dihydroxy-L-phenylalanine
3,4-Dihydroxyphenyl-L-alanine
3,4-Dihydroxyphenylalanine
3,4-Dihydroxyphenylalanine (VAN)
3,4-dihydroxy-L-phenylalanine
3,4-dihydroxyphenylalanine
3-(3,4-Dihydroxypheny
3-(3,4-Dihydroxyphenyl)-L-alanine
3-Hydroxy-L-tyrosine
34241-25-3
37830_FLUKA
587-45-1
59-92-7
72572-99-7
72573-00-3
88250-23-1
90638-38-3
AC-11686
AC1L1LOR
AC1Q4U7F
BIDD:GT0158
BPBio1_000059
BSPBio_000053
BSPBio_002354
Bendopa
Bio-0575
Biodopa
Brocadopa
C00355
C9H11NO4
CAS-59-92-7
CCRIS 3766
CHEBI:15765
CHEMBL1009
CID6047
Cerepap
Cidandopa
D 9628
D00059
D0600
D9628
D9628_SIGMA
DAH
DB01235
DOPA
Deadopa
Dihydroxy-L-phenylalanine
Dihydroxyphenylalanine
DivK1c_000452
Dopa
Dopaflex
Dopaidan
Dopal
Dopal-Fher
Dopal-fher
Dopalina
Dopar
Dopar (TN)
Doparkine
Doparl
Dopasol
Dopaston
Dopaston SE
Dopastone
Dopastral
Dopicar
Doprin
EINECS 200-445-2
EU-0100454
Eldopal
Eldopar
Eldopatec
Eurodopa
HMS1568C15
HMS1922J14
HMS2090O08
HMS2093N04
HMS501G14
HSDB 3348
Helfo DOPA
 
Helfo-Dopa
Helfo-dopa
IDI1_000452
IV Levodopa
InChI=1/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14
Insulamina
KBio1_000452
KBio2_000934
KBio2_003502
KBio2_006070
KBioGR_001177
KBioSS_000934
L Dopa
L(-)-Dopa
L-(-)-Dopa
L-(3, 4-Dihydroxyphenyl)-.alpha.-alani
L-(3, 4-Dihydroxyphenyl)alanine
L-(o-Dihydroxyphenyl)alanine
L-.Beta.-(3,4-Dihydroxyphenyl)alanine
L-3,4-Dihydroxyphenylalanine
L-3,4-dihydroxyphenylalanine
L-3-(3,4-Dihydroxyphenyl)-Alanine
L-3-(3,4-Dihydroxyphenyl)alanine
L-3-Hydroxytyrosine
L-4-5-Dihydroxyphenylalanine
L-DOPA
L-DOPA, Parcopa, Atamet, Stalevo, Madopar, Prolopa, Dopar, 3,4-Dihydroxyphenylalanine, Levodopa
L-Dihydroxyphenylalanine
L-Dopa
L-O-Dihydroxyphenylalanine
L-b-(3,4-Dihydroxyphenyl)-a-alanine
L-beta-(3,4-Dihydroxyphenyl)-alpha-alanine
L-beta-(3,4-Dihydroxyphenyl)alanine
L-o-Hydroxytyrosine
LS-255
Laradopa
Larodopa
Ledopa
Levedopa
Levodopa
Levodopa (JP15/USP)
Levodopa (JP15/USP/INN)
Levodopa [USAN:INN:BAN:JAN]
Levodopum
Levodopum [INN-Latin]
Levopa
Lopac-D-9628
Lopac0_000454
MLS000028514
Maipedopa
MolPort-000-856-937
NCGC00015384-01
NCGC00016270-01
NCGC00016270-06
NCGC00093869-04
NINDS_000452
NSC 118381
NSC118381
PDSP1_001541
PDSP2_001525
Parda
Pardopa
Prestwick0_000017
Prestwick1_000017
Prestwick2_000017
Prestwick3_000017
Prestwick_185
Prodopa
Ro 4-6316
S1726_Selleck
SDCCGMLS-0066924.P001
SMR000058312
SPBio_000391
SPBio_001974
SPECTRUM2300205
Sobiodopa
Spectrum2_000496
Spectrum4_000539
Spectrum5_001899
Spectrum_000454
Syndopa
UNII-46627O600J
Veldopa
Weldopa
b-(3,4-Dihydroxyphenyl)-L-alanine
b-(3,4-Dihydroxyphenyl)-a-L-alanine
b-(3,4-Dihydroxyphenyl)alanine
beta-(3,4-Dihydroxyphenyl)-L-alanine
beta-(3,4-Dihydroxyphenyl)-alpha-L-alanine
beta-(3,4-Dihydroxyphenyl)-alpha-alanine
beta-(3,4-Dihydroxyphenyl)alanine
bmse000322
component of Sinemet
l)-L-alanine
nchembio.2007.55-comp26
nchembio.89-comp9
ne
β-(3,4-dihydroxyphenyl)alanine
6
DopamineapprovedPhase 4375951-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
7Adrenergic alpha-AntagonistsPhase 4727
8Adrenergic AgentsPhase 45140
9Adrenergic AntagonistsPhase 41535
10Adrenergic alpha-1 Receptor AntagonistsPhase 4470
11Antihypertensive AgentsPhase 44095
12Anti-Infective AgentsPhase 4, Phase 3, Phase 221402
13onabotulinumtoxinAPhase 4, Phase 3, Phase 2626
14Dopamine AgentsPhase 43759
15Antiparkinson AgentsPhase 41527
16Antidepressive AgentsPhase 4, Phase 12666
17Psychotropic DrugsPhase 4, Phase 16279
18Mandelic AcidsPhase 4, Phase 3, Phase 255
19Neurotransmitter AgentsPhase 4, Phase 3, Phase 2, Phase 117734
20Cholinergic AntagonistsPhase 4, Phase 3, Phase 2, Phase 11658
21Cholinergic AgentsPhase 4, Phase 3, Phase 2, Phase 13846
22Neuromuscular AgentsPhase 4, Phase 3, Phase 2, Phase 11129
23Autonomic AgentsPhase 4, Phase 3, Phase 29774
24ParasympatholyticsPhase 4, Phase 3, Phase 21050
25Muscarinic AntagonistsPhase 4, Phase 3, Phase 2, Phase 11134
26Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 2, Phase 122776
27incobotulinumtoxinAPhase 4, Phase 3, Phase 2635
28Botulinum ToxinsPhase 4, Phase 3, Phase 2, Phase 1669
29Botulinum Toxins, Type APhase 4, Phase 3, Phase 2, Phase 1630
30Renal AgentsPhase 4, Phase 3, Phase 2732
31abobotulinumtoxinAPhase 4, Phase 3, Phase 2626
32SageNutraceuticalPhase 446
33
Bupivacaineapproved, investigationalPhase 211312180-92-9, 38396-39-32474
Synonyms:
( inverted exclamation markA)-bupivacaine
(+-)-Bupivacaine
(1)-1-Butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
(RS)-bupivacaine
(±)-bupivacaine
1-Butyl-2',6'-pipecoloxylidide
1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide
1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
15233-43-9
2180-92-9
38396-39-3
AB00053674
AC-2096
AC1L1DRE
AC1Q5LX4
AH 250
AKOS001637202
AR-1A0242
Anekain
BPBio1_000298
BRD-A01636364-003-05-2
BSPBio_000270
BSPBio_002607
Bio-0886
Bloqueina
Bucaine
Bucaine (TN)
Bupivacaina
Bupivacaina [INN-Spanish]
Bupivacaine (INN)
Bupivacaine Carbonate
Bupivacaine HCL
Bupivacaine HCL KIT
Bupivacaine Monohydrochloride, Monohydrate
Bupivacaine [INN:BAN]
Bupivacainum
Bupivacainum [INN-Latin]
Bupivan
C07529
C18H28N2O
CBupivacaine
CHEBI:3215
CHEMBL1098
CID2474
Carbostesin
D07552
DB00297
DL-Bupivacaine
DUR-843
 
DepoBupivacaine
DivK1c_000758
EINECS 218-553-3
EINECS 253-911-2
HMS2090F12
IDI1_000758
KBio1_000758
KBio2_002004
KBio2_004572
KBio2_007140
KBio3_001827
KBioGR_001516
KBioSS_002004
KST-1A4609
L000695
LAC-43
LS-109841
LS-2222
MLS001361336
Marcaina
Marcaine
Marcaine HCL
Marcaine Spinal
MolPort-004-955-820
NCGC00178579-01
NCGC00178579-02
NINDS_000758
NSC119660
Prestwick0_000305
Prestwick1_000305
Prestwick2_000305
Prestwick3_000305
SMR000058218
SPBio_001558
SPBio_002489
Sensorcaine
Sensorcaine-MPF
Sensorcaine-MPF Spinal
Spectrum2_001589
Spectrum3_000974
Spectrum4_001098
Spectrum5_001483
Spectrum_001524
Transdur-Bupivacaine
UNII-Y8335394RO
Win 11318
Win 11318 HCl
bupivacaine
cBupivacaine
dl-1-Butyl-2',6'-pipecoloxylidide
racemic bupivacaine
34
Etanerceptapproved, investigationalPhase 1, Phase 2397185243-69-0
Synonyms:
185243-69-0
CD120b
D00742
Enbrel
Enbrel (TN)
Enbrel Sureclick
Etanercept
Etanercept (USAN/INN)
 
Etanercept (genetical recombination)
Etanercept (genetical recombination) (JAN)
TNF-R2
Tumor necrosis factor receptor 2
Tumor necrosis factor receptor superfamily member 1B precursor
Tumor necrosis factor receptor type II
etanercept
p75
p80 TNF-alpha receptor
35
MentholapprovedPhase 223532216-51-516666
Synonyms:
(−
()-Menthol
(+)-Neo-menthol
(+)-p-Menthan-3-ol
(+-)-(1R*,3R*,4S*)-Menthol
(+-)-Menthol
(+/-)-Menthol
(+/-)-p-Menthan-3-ol
(-)-(1R,3R,4S)-Menthol
(-)-Menthyl alcohol
(-)-menthol
(-)-p-Menthan-3-ol
(-)-trans-p-Menthan-cis-ol
(1R)-(-)-Menthol
(1R,2S,5R)-(-)-menthol
(1R,2S,5R)-Menthol
(1R,3R,4S)-(-)-MENTHOL
(1R,3R,4S)-(-)-Menthol
(1R-(1-alpha,2-beta,5-alpha))-5-Methyl-2-(1-methylethyl)cyclohexanol
(1S, 2S, 5R)-(+)-Neomenthol
(1S,2R,5R)-(+)-Isomenthol
(1S,2R,5S)-(+)-Menthol
(1S,2R,5S)-Menthol
(1alpha,2beta,5alpha)-5-Methyl-2(1-methylethyl)cyclohexanol
(1r,2s,5r)-(-)-menthol
(L)-MENTHOL
(R)-(-)-Menthol
(r)-(-)-menthol
)-Menthol
--MENTHOL
1-Menthol
1490-04-6
15356-60-2
15356-70-4
15785_RIEDEL
15785_SIAL
19863P
2-Isopropyl-5-methylcyclohexanol
20747-49-3
2216-51-5
3-p-Menthol
4-Isopropyl-1-methylcyclohexan-3-ol
491-02-1
5-Methyl-2-(1-methylethyl)-cyclohexanol
5-Methyl-2-(1-methylethyl)cyclohexanol
5-methyl-2-(propan-2-yl)cyclohexanol
5-methyl-2-propan-2-ylcyclohexan-1-ol
551376_ALDRICH
551376_FLUKA
588733_ALDRICH
613290_ALDRICH
613290_FLUKA
63660_FLUKA
63670_ALDRICH
63670_FLUKA
63975-60-0
6C6A4A8C-A054-468C-A1F0-F29E39838CF2
89-78-1
98167-53-4
AC1L1B2E
AC1L28FR
AC1Q1NQ2
AC1Q2QQM
AI3-08161
AI3-52408
AKOS000119740
AR-1J3337
BB_NC-0057
BRN 1902288
BRN 3194263
BSPBio_003062
C00400
C10H20O
CCRIS 3728
CCRIS 375
CCRIS 4666
CCRIS 9231
CHEBI:15409
CHEBI:545611
CHEMBL256087
CHEMBL470670
CID1254
CID16666
Caswell No. 540
D-(-)-Menthol
D-p-Menthan-3-ol
D00064
D008610
D04849
D04918
DB00825
DivK1c_000820
EINECS 201-939-0
EINECS 207-724-8
EINECS 216-074-4
EINECS 218-690-9
EINECS 239-387-8
EINECS 239-388-3
EPA Pesticide Chemical Code 051601
FEMA No. 2665
Fisherman's friend lozenges
Fisherman's friend lozenges (TN)
HMS1922G13
HMS2092L14
HMS502I22
 
HSDB 5662
HSDB 593
Headache crystals
Hexahydrothymol
I06-1216
I14-7371
IDI1_000820
KBio1_000820
KBio2_000785
KBio2_003353
KBio2_005921
KBio3_002562
KBioSS_000785
L-(-)-Menthol
L-(-)-menthol
L-Menthol
L-menthol
LMPR0102090001
LS-2353
LS-57201
LS-886
LS-89531
LS-89533
Levomenthol
Levomenthol [INN:BAN]
Levomentholum
Levomentholum [INN-Latin]
Levomentol
M0321
M0545
M2772_SIAL
MENTHOL
MLS002207256
Menthacamphor
Menthol
Menthol (USP)
Menthol (VAN)
Menthol natural
Menthol natural, brazilian
Menthol racemic
Menthol racemique
Menthol racemique [French]
Menthol solution
Menthol, (1alpha,2beta,5alpha)-Isomer
Menthomenthol
Menthyl alcohol
MolPort-000-849-729
MolPort-001-793-392
NCGC00159382-02
NCGC00159382-03
NCGC00164247-01
NCGC00164247-02
NCI-C50000
NINDS_000820
NOOLISFMXDJSKH-KXUCPTDWBX
NSC 2603
NSC 62788
NSC2603
NSC62788
Neoisomenthol
Peppermint camphor
RACEMIC MENTHOL U.S.P.
Racementhol
Racementhol [INN:BAN]
Racementholum
Racementholum [INN-Latin]
Racementol
Racementol [INN-Spanish]
Racemic menthol
Robitussin Cough Drops
SDCCGMLS-0066659.P001
SMR001306785
SPBio_000869
SPECTRUM1503134
STK802468
Spectrum2_000855
Spectrum3_001561
Spectrum5_001060
Spectrum_000305
Tra-kill tracheal mite killer
U.S.P. Menthol
U.S.p. Menthol
UNII-BZ1R15MTK7
UNII-L7T10EIP3A
UNII-YS08XHA860
W266507_ALDRICH
W266523_ALDRICH
W266590_ALDRICH
WLN: L6TJ AY1&1 BQ D1
WLN: L6TJ AY1&1 DQ D1 -L
ZINC01482164
cis-1 ,3-trans-1,4-(+-)-menthol
cis-1,3-trans-1,4-(+-)-menthol
d,l-Menthol
d-Menthol
d-Neomenthol
dl-3-p-Menthanol
dl-Menthol
dl-Menthol (JP15)
l-(-)-Menthol
l-Menthol
l-Menthol (JP15)
l-Menthol (TN)
l-Menthol (natural)
nchembio862-comp1
p-Menthan-3-ol
rac-Menthol
36AnestheticsPhase 2, Phase 19001
37Central Nervous System DepressantsPhase 212806
38rimabotulinumtoxinBPhase 2, Phase 117
39Pharmaceutical SolutionsPhase 2, Phase 17793
40BromidesPhase 2, Phase 1606
41Anesthetics, LocalPhase 23272
42AnalgesicsPhase 1, Phase 211287
43Anti-Inflammatory Agents, Non-SteroidalPhase 1, Phase 24295
44Analgesics, Non-NarcoticPhase 1, Phase 26260
45Antirheumatic AgentsPhase 1, Phase 210627
46Immunosuppressive AgentsPhase 1, Phase 212770
47AutoantibodiesPhase 1, Phase 2126
48Anti-Inflammatory AgentsPhase 1, Phase 210355
49Gastrointestinal AgentsPhase 1, Phase 28109
50
GlycopyrrolatePhase 1160596-51-03494
Synonyms:
(1,1-dimethylpyrrolidin-1-ium-3-yl) 2-cyclopentyl-2-hydroxy-2-phenylacetate
(1,1-dimethylpyrrolidin-1-ium-3-yl) 2-cyclopentyl-2-hydroxy-2-phenylacetate bromide
.beta.-1-Methyl-3-pyrrolidyl-.alpha.-cyclopentylmandelate methobromide
1,1-Dimethyl-3-hydroxypyrrolidinium bromide .alpha.-cyclopentylmandelate
1,1-Dimethyl-3-hydroxypyrrolidinium bromide alpha-cyclopentylmandelate
1-Methyl-3-pyrrolidinyl .alpha.-phenylcyclopentaneglycolate methobromide
1-Methyl-3-pyrrolidyl alpha-phenylcyclopentaneglycolate methobromide
3-(erythro-2-Cyclopentyl-2-hydroxy-2-phenylacetoxy)-1,1-dimethylpyrrolidiniumbromid
3-Hydroxy-1,1-dimethylpyrrolidinium bromide .alpha.-cyclopentylmandelate
3-Hydroxy-1,1-dimethylpyrrolidinium bromide alpha-cyclopentylmandelate
3-Hydroxy-1,1-dimethylpyrrolidinium bromide-.alpha.-cyclopentylmandelate
53808-86-9
596-51-0
AB00513912
AC-15990
AC1L1G28
AC1L1XX0
AC1LAW54
AC1Q1RGS
AC1Q60WT
AD-237
AHR 504
AHR-504
AR-1J1255
Asecryl
BPBio1_000806
BSPBio_000732
Bromure de glycopyrronium
Bromure de glycopyrronium [INN-French]
Bromure de ritropirronio
Bromure de ritropirronium
Bromuro de glicopirronio
Bromuro de glicopirronio [INN-Spanish]
C19H28NO3
CHEMBL1201027
CHEMBL1201335
CID11693
CID3494
CID521843
CPD000469282
Copyrrolate
Cuvposa
D00540
DB00986
EINECS 209-887-0
GLYCOPYRROLATE
Gastrodyn
Glycopyrrolate (USP)
Glycopyrrolate [USAN]
Glycopyrrolate bromide
Glycopyrroni bromidum
Glycopyrronii bromidum
 
Glycopyrronii bromidum [INN-Latin]
Glycopyrronium
Glycopyrronium bromide
Glycopyrronium bromide (JAN/INN)
HMS1570E14
HMS2051P12
HMS2094A05
I14-3643
L001045
LS-138344
MLS001424112
MLS002222301
Mandelic acid, .alpha.-cyclopentyl-, ester with 3-hydroxy-1,1-dimethylpyrrolidinium bromide
MolPort-002-885-831
NCGC00179456-01
NSC 250836
NSC 251251
NSC 251252
NSC250836
NSC251251
NSC251252
NVA 237
NVA-237
Nodapton
PT-001
Prestwick0_000746
Prestwick1_000746
Prestwick2_000746
Prestwick3_000746
Pyrrolidinium, 1,1-dimethyl-3-hydroxy-, bromide, alpha-cyclopentylmandelate
Pyrrolidinium, 3-((cyclopentylhydroxyphenylacetyl)oxy)-1,1-dimethyl-, bromide
Pyrrolidinium, 3-[(cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethyl-, bromide
Pyrrolidinium, 3-hydroxy-1,1-dimethyl-, bromide, .alpha.-cyclopentylmandelate
Pyrrolidinium, 3-hydroxy-1,1-dimethyl-, bromide, alpha-cyclopentylmandelate
Pyrrolidinium, 3-hydroxy-1,1-dimethyl-, bromide, alpha-cyclopentylmandelate (8CI)
ROBINUL FORTE
Ritropirronium bromide
Ritropirronium bromide [INN]
Robanul
Robinal
Robinul
Robinul (TN)
SAM001246629
SAM002589987
SMR000469282
SPBio_002671
ST51054976
Salt*)
Tarodyl
Tarodyn
UNII-V92SO9WP2I
WLN: T5KTJ A1 A1 COVXQR&- AL5TJ &Q &E
glycopyrronium bromide

Interventional clinical trials:

(show top 50)    (show all 71)
idNameStatusNCT IDPhase
1Use of Oxybutynin for Treating Hyperhidrosis: A Placebo-control StudyCompletedNCT01310712Phase 4
2VASER Treatment of Axillary Hyperhidrosis/BromidrosisCompletedNCT00735293Phase 4
3A Study Using Botulinum Toxin Type A in Adolescents With Axillary HyperhidrosisCompletedNCT00168415Phase 4
4A Study Using Botulinum Toxin Type A in Patients With Axillary HyperhidrosisCompletedNCT00168480Phase 4
5Excessive Sweating Caused by Antidepressants: Measurement and Treatment With TerazosinCompletedNCT00449683Phase 4
6Duodenal Levodopa Infusion, Quality of Life and Autonomic Nervous System in Parkinson's DiseaseCompletedNCT00914134Phase 4
7Unicentric Comparing Study of Suction Curettage With Standard BOTOX Injection in the Treatment of Patients With Essential Axillar Hyperhidrosis: Comparing of Efficacy, Duration of Effectiveness, and Adverse Events.TerminatedNCT00669474Phase 4
8Efficacy and Safety of Sage Tablets Compared to Placebo in Menopausal Patients With Hot Flushes and SweatingTerminatedNCT02032862Phase 4
9Treatment of Hyperhidrosis With OxybutyninCompletedNCT01855256Phase 3
10A Study Using Botulinum Toxin Type A in Patients With Axillary HyperhidrosisCompletedNCT00168402Phase 3
11Long-term Safety Study of DRM04 in Subjects With Primary Axillary HyperhidrosisCompletedNCT02553798Phase 3
12GSK1358820 (Botulinum Toxin A) PhIII DB & OL Study in Patients With Axillary HyperhidrosisCompletedNCT01128738Phase 3
13Study of DRM04 in Subjects With Axillary HyperhidrosisCompletedNCT02530294Phase 3
14Study of DRM04 in Axillary HyperhydrosisCompletedNCT02530281Phase 3
15Liposuction as Treatment for Excessive Axillary SweatCompletedNCT00228072Phase 2, Phase 3
16The Use of Human Acellular Dermal Matrix to Improve Infraauricular Depressed Deformities and Frey's SyndromeCompletedNCT01414790Phase 3
17BTX-A Treatment for Palmar HyperhidrosisTerminatedNCT01262339Phase 2, Phase 3
18Evaluate the Efficacy of Oxybutynin Chloride in Patients With Primary HyperhidrosisWithdrawnNCT02099695Phase 3
19A Study to Compare Oxybutynin to a Placebo in Women and the Effect on Plantar HyperhidrosisCompletedNCT01328015Phase 2
20A Study to Evaluate Clinical Effect, Pharmacokinetics , Safety, and Tolerability of Umeclidinium in Palmar Hyperhidrosis SubjectsCompletedNCT02673619Phase 2
21Pharmacokinetic, Safety, Tolerability, and Clinical Effect of Topical Umeclidinium in Primary Axillary HyperhidrosisCompletedNCT02563899Phase 2
22Clinical Trial To Evaluate ANT-1207 In Subjects With Primary Axillary HyperhidrosisCompletedNCT02479139Phase 2
23A Dose-Ranging Study of the Effect of DRM04B in Subjects With Axillary HyperhidrosisCompletedNCT02016885Phase 2
24A Safety and Efficacy Study of BBI-4000 in Subjects With Axillary HyperhidrosisCompletedNCT02336503Phase 2
25Comparator Study of the Effect of DRM04B and DRM 04 in Subjects With Axillary HyperhidrosisCompletedNCT02129660Phase 2
26A Safety, Tolerability and Preliminary Efficacy Study of BBI-4000 Gel in Subjects With Palmar HyperhidrosisCompletedNCT02682238Phase 2
27Clinical Trial to Evaluate ANT-1403 in the Treatment of Primary Axillary HyperhidrosisCompletedNCT01799824Phase 2
28Safety and Efficacy of an Anticholinergic Agent for Treatment of Primary Axillary HyperhidrosisCompletedNCT02193139Phase 2
29Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Primary Axillary HyperhidrosisCompletedNCT02565732Phase 2
30Botulinum Toxin Treatment in Craniofacial, Inguinal, Palmar, Plantar and Truncal HyperhidrosisRecruitingNCT01930604Phase 2
31A Confirmatory Safety and Efficacy Study of BBI-4000 in Subjects With Axillary HyperhidrosisRecruitingNCT03024255Phase 2
32ASIS for Enbrel in Plaque PsoriasisNot yet recruitingNCT02112097Phase 1, Phase 2
33SGB in Post-Menopausal WomenNot yet recruitingNCT02907983Phase 2
34Skin Sympathetic Nerve Activity and Cardiac ArrhythmiasNot yet recruitingNCT02939469Phase 2
35A Safety, Tolerability and Preliminary Efficacy Study of BBI-4000 in Subjects With Axillary HyperhidrosisCompletedNCT02058264Phase 1
36Study to Assess the Efficacy of Botulinum Toxin B (Myobloc) for the Treatment of Prosthesis-associated SweatingCompletedNCT01671800Phase 1
37Characterization of Exposure From Topical Administration of [14C] Umeclidinium to Axilla or Palm of Healthy Male SubjectsCompletedNCT01934153Phase 1
38Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Glycopyrrolate (AIDES-G)TerminatedNCT01588717Phase 1
39Tx Axillary Hyperhidrosis 1210nm Diode LaserUnknown statusNCT02105753
40Comparison of Methods of Lumbar Sympathetic Ganglion Block: Distance vs AngleUnknown statusNCT01648543
41Inherited Myokymia: A Clinical and Genetic Study of a FamilyUnknown statusNCT01250704
42Unilateral Sequential Sympathectomy for Palmar HyperhidrosisCompletedNCT02321332
43The Use of Topical Oxybutynin 10% for Treating Primary Focal Hyperhidrosis-axillary, Palmar and Plantar.CompletedNCT02973659
44Long Term Results of the Use of Oxybutynin for the Treatment of HyperhidrosisCompletedNCT01956591
45Objective Evaluation of Patients With Palmar Hyperhidrosis Submitted to Two Levels of Sympathectomy: T3 and T4.CompletedNCT01140659
46Clinical Evaluation of the miraDry System in Subjects With HyperhidrosisCompletedNCT01091129
47Staged Extended Thoracoscopic Sympathicotomy for Palmo-axillo-plantar HyperhidrosisCompletedNCT02728297
48Use of Oxybutynin to Treat Axillary HyperhidrosisCompletedNCT01118429
49Botox and Suction-Curettage for Treatment of Excessive Underarm Sweating (Axillary Hyperhidrosis)CompletedNCT01274611
50Cardiac Autonomic Changes After Endoscopic Thoracic Sympathectomy For Essential Palmar HyperhidrosisCompletedNCT02733497

Search NIH Clinical Center for Cold-Induced Sweating Syndrome 1


Cochrane evidence based reviews: hyperhidrosis

Genetic Tests for Cold-Induced Sweating Syndrome 1

About this section

Genetic tests related to Cold-Induced Sweating Syndrome 1:

id Genetic test Affiliating Genes
1 Cold-Induced Sweating Syndrome 127
2 Cold-Induced Sweating Syndrome27

Anatomical Context for Cold-Induced Sweating Syndrome 1

About this section

MalaCards organs/tissues related to Cold-Induced Sweating Syndrome 1:

36
Skin

Publications for Cold-Induced Sweating Syndrome 1

About this section

Variations for Cold-Induced Sweating Syndrome 1

About this section

UniProtKB/Swiss-Prot genetic disease variations for Cold-Induced Sweating Syndrome 1:

70 (show all 14)
id Symbol AA change Variation ID SNP ID
1CRLF1p.Arg81HisVAR_017865rs104894670
2CRLF1p.Leu374ArgVAR_017866rs104894668
3CRLF1p.Trp76GlyVAR_033113rs137853143
4CRLF1p.Leu74ProVAR_070817
5CRLF1p.Tyr75AspVAR_070818
6CRLF1p.Asn113IleVAR_070819
7CRLF1p.Leu114ProVAR_070820rs774359694
8CRLF1p.Pro138LeuVAR_070821rs137853930
9CRLF1p.Ser145ProVAR_070822
10CRLF1p.Arg216CysVAR_070823rs556029569
11CRLF1p.Phe268SerVAR_070824rs761982168
12CRLF1p.Trp284CysVAR_070825rs137853927
13CRLF1p.Arg312ProVAR_070826
14CRLF1p.Arg340CysVAR_070827rs771459625

Clinvar genetic disease variations for Cold-Induced Sweating Syndrome 1:

5 (show all 18)
id Gene Variation Type Significance SNP ID Assembly Location
1CRLF1NM_004750.4(CRLF1): c.857_864delTGGTGGAC (p.Val286Glyfs)deletionPathogenicrs367543004GRCh37Chr 19, 18707592: 18707599
2CRLF1NM_004750.4(CRLF1): c.1121T> G (p.Leu374Arg)SNVPathogenicrs104894668GRCh37Chr 19, 18705148: 18705148
3CRLF1NM_004750.4(CRLF1): c.303delC (p.Asn102Thrfs)deletionPathogenicrs137853931GRCh37Chr 19, 18710469: 18710469
4CRLF1NM_004750.4(CRLF1): c.31_53del23 (p.Gln11Valfs)deletionPathogenicrs137853929GRCh37Chr 19, 18717414: 18717436
5CRLF1NM_004750.4(CRLF1): c.397+1G> ASNVPathogenicrs137853932GRCh37Chr 19, 18710374: 18710374
6CRLF1NM_004750.4(CRLF1): c.413C> T (p.Pro138Leu)SNVPathogenicrs137853930GRCh37Chr 19, 18709696: 18709696
7CRLF1NM_004750.4(CRLF1): c.538C> T (p.Gln180Ter)SNVPathogenicrs137853926GRCh37Chr 19, 18709401: 18709401
8CRLF1NM_004750.4(CRLF1): c.852G> T (p.Trp284Cys)SNVPathogenicrs137853927GRCh37Chr 19, 18707705: 18707705
9CRLF1NM_004750.4(CRLF1): c.935G> A (p.Arg312His)SNVPathogenicrs137853933GRCh37Chr 19, 18707521: 18707521
10CRLF1NM_004750.4(CRLF1): c.713dupC (p.Pro239Alafs)duplicationPathogenicrs768727082GRCh38Chr 19, 18597034: 18597034
11CRLF1NM_004750.4(CRLF1): c.845_846delTG (p.Val282GlyfsTer47)deletionPathogenicrs137853928GRCh38Chr 19, 18596901: 18596902
12CRLF1CRLF1, 1-BP INS, 676AinsertionPathogenicChr na, -1: -1
13CRLF1NM_004750.4(CRLF1): c.226T> G (p.Trp76Gly)SNVPathogenicrs137853143GRCh37Chr 19, 18710546: 18710546
14CRLF1CRLF1, 527+5G-ASNVPathogenicChr na, -1: -1
15CRLF1CRLF1, 1-BP DUP, 713CduplicationPathogenicChr na, -1: -1
16CRLF1NM_004750.4(CRLF1): c.1102A> T (p.Lys368Ter)SNVPathogenicrs137853144GRCh37Chr 19, 18705167: 18705167
17CRLF1CRLF1, 2-BP DEL/1-BP INS, NT708indelPathogenicChr na, -1: -1
18CRLF1NM_004750.4(CRLF1): c.829C> T (p.Arg277Ter)SNVPathogenicrs137853145GRCh37Chr 19, 18707728: 18707728

Expression for genes affiliated with Cold-Induced Sweating Syndrome 1

About this section
Search GEO for disease gene expression data for Cold-Induced Sweating Syndrome 1.

GO Terms for genes affiliated with Cold-Induced Sweating Syndrome 1

About this section

Cellular components related to Cold-Induced Sweating Syndrome 1 according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1CNTFR-CLCF1 complexGO:00970599.6CLCF1, CNTFR
2CRLF-CLCF1 complexGO:00970589.1CLCF1, CNTF, CRLF1

Biological processes related to Cold-Induced Sweating Syndrome 1 according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1ciliary neurotrophic factor-mediated signaling pathwayGO:00701209.5CNTF, CNTFR, LIFR
2negative regulation of neuron apoptotic processGO:00435249.3CLCF1, CNTF, CNTFR, CRLF1
3positive regulation of tyrosine phosphorylation of Stat3 proteinGO:00425179.1CLCF1, CNTF, CRLF1
4positive regulation of cell proliferationGO:00082848.6CLCF1, CNTF, CNTFR, CRLF1, LIFR

Molecular functions related to Cold-Induced Sweating Syndrome 1 according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1ciliary neurotrophic factor receptor activityGO:000489710.2CNTFR, LIFR
2cytokine bindingGO:00199559.8CNTFR, CRLF1, LIFR
3cytokine activityGO:00051259.8CLCF1, CNTF, CRLF1
4ciliary neurotrophic factor receptor bindingGO:00051279.4CLCF1, CNTF, CRLF1, LIFR
5protein heterodimerization activityGO:00469829.3CLCF1, CRLF1, LIFR

Sources for Cold-Induced Sweating Syndrome 1

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet